EULAR 2021 - Day 2 Podcasts Check out this compilation of our EULAR 2021 Day 2 broadcasts below. You can also follow the EULAR 2021 RheumNow podcasts on iTunes and Soundcloud. https://t.co/GskToSkfLk https://t.co/nF2FkHgBtu

• https://bit.ly/3vTTxdM

HUR-BIO real life data, PsA pts started bDMARDs w/in 18 mo of dx vs almost 3x later in RA pts (tended to remain on csDMARDs.) This distinction may be explained by synthetic DMARDs on activity differences between the RA & PsA. Abstract #POS0633 #EULAR2021 https://t.co/VkkF28jm2f https://t.co/IkfGdZYNY3

• http://ow.ly/zQ7B50F3Gag

Poster #POS0633 detailed HUR-BIO PsA pts started bDMARDs w/in 18 months of dx vs, on ave, 3x longer to start bDMARDs in RA pts in real life data. What do you drugs do you start in your PsA pts after dx? Feel free to detail me below! #EULAR2021 @RheumNow

Which biomarkers could guide csDMARDs tapering in #RA patients in #remission? Dr Gul reported in a cohort study using a tapering protocol, 35% had relapsed. Risk score for sustained remission comprise IRC<2%, MSK-US PD=0 and RAQoL=<1 (AUC=0.89) #EULAR2021 #OP0182 @RheumNow https://t.co/y1Y6ug7f3w

PS0103 #EULAR2021. Do you adjust complement levels by time of pregnancy? ⭐️Mean C3 ⬆️28% compared to 1st trimester ⭐️Mean C4 ⬆️ 11% compared to 1st trimester @RheumNow

#EULAR2021 LB0004: Secukinumab for enthesitis-related JIA treatment-withdrawal study shows longer time to flare and decreased flares compared to PBO @Rheumnow https://t.co/LG3dDmH7we

Looking for RA specific coverage? We've got you covered. #EULAR2021 https://t.co/eXD5UK2RRp https://t.co/RI3aMW2E2g

• https://bit.ly/3pl2dXY

JUNIPERA trial: open label Secukinumab in ERA and JPsA: 90.4% JIA ACR 30 and 69.9% JIA ACR 70 W12 and > time to flare W104, 72% risk of flare reduction SEC vs PBO (HR: 0.28 95CI: 0.13–0.63 P<0.001). No particular safety signal. #LB0002 @Rheumnow #EULAR2021 https://t.co/PJ9NYi25UI

DANBIO + Swedish register SGR linked to national birth registers (matched 1:10): RA-pregnancies: higher preterm birth (OR 1.92, 95CI 1.56-2.35) and small gestational age (OR 1.93, 95CI 1.45-2.57). Association strengthened by high disease activity. #OP0210 @Rheumnow #EULAR2021 https://t.co/Fjm0uxCPgC

What is the impact of RA on fertility in men: #OP0211 and #OP0212 @Rheumnow #EULAR2021

Retrospective RA cohort study: overall risk of dementia ⬆️ in RA (HR 1.38; 95%CI 1.04-1.83) BUT 10-year cumulative incidence of dementia ⬇️: 12.7% in 1980s 7.2% in 1990s 2000s 6.2% Risk no longer significantly ⬆️ for patients w/ RA onset in 2000s! @RheumNow #EULAR2021 #OP0216 https://t.co/TVRTTJjvno

Serious infections and BioDMARDs: what is the confounding factor? BSRBR-RA: 33,916 RA treated w/ BioDMARDs with 62,532 years of follow-up, 2036 SI. HR of SI no longer different among BioDMARDs when adjusted for the line of therapy! #OP0241@Rheumnow #EULAR2021 https://t.co/UG9WrXP7RD

HOT🔥: thermography of hands in IA remotely collected via smartphone correlates w/ US features 0.48, p<0.01 and SJC 0.48, p<0.01), DAS28 (0.73, p<0.01), CDAI (0.84, p<0.01) and SDAI (0.82, p<0.01). A future tool for patients remote follow-up? #OP0300 @Rheumnow #EULAR2021 https://t.co/MJLpz6eqIy